Dendritic cells are functionally defective in multiple myeloma: The role of interleukin-6

Blood

Volumn 100, Issue 1, 2002, Pages 230-237

  Ratta, Marina ^a,b,c   Fagnoni, Francesco ^a,b,c   Curti, Antonio ^a,b,c   Vescovini, Rosanna ^a,b,c   Sansoni, Paolo ^a,b,c   Oliviero, Barbara ^a,b,c   Fogli, Miriam ^a,b,c   Ferri, Elisa ^a,b,c   Cuna, Gioacchino Robustelli Della ^a,b,c   Tura, Sante ^a,b,c   Baccarani, Michele ^a,b,c   Lemoli, Roberto M ^a,b,c,d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c IRCCS   (Italy)

^d Institute of Haematology Lorenzo e Ariosto Seràgnoli   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD1 ANTIGEN; CD14 ANTIGEN; CD34 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MULTIPLE MYELOMA; PHAGOCYTOSIS; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0036659945     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V100.1.230     Document Type: Article

References (34)

1. Klein B, Zhang X-E, Lu Z-Y, Bataille R. Interleukin-6 in human multiple myeloma. Blood. 1995;85:863-872.
2. Klein B, Zhang X-G, Jourdan M, et al. A paracrine but not autocrine regulation of plasma cell growth and differentiation by interleukin-6. Blood. 1989;73:517-526.
3. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myeloma. Nature. 1988;332:83-85.
4. Bataille R, Jourdan M, Zhang X-G, Klein B. Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias. J Clin Invest. 1989;84:2008-2011.
5. Ludwig H, Nachbaur DM, Fritz E, Krainer M, Huber H. Interleukin-6 is a prognostic factor in multiple myeloma. Blood. 1991;77:2794-2795.
6. Blay JY, Negrier S, Combaret V, et al. Serum level of interleukin-6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992;52:3317.
7. Tartour E, Blay JY, Dorval T, et al. Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: a French multiinstitutional study. J Clin Oncol. 1996;14:1697.
8. Deehan DJ, Heyes SD, Simpson WG, Broom J, Franks C, Eremin O. In vivo cytokine production and recombinant interleukin-2 immunotherapy: an insight into the possible mechanisms underlying clinical responses. Br J Cancer. 1994;69:1130.
9. Bataille R, Barlogie B, Lu ZY et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood. 1995;86:685-691.
10. Bancherau J, Steinman RM. Dendritic cells and the control of immunity. Nature, 1988;392:245-252.
11. + progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor, Blood. 1998;92:4778-4791.
12. Chomarat P, Bancherau J, Davoust J, Palucka AK. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol. 2000;1:510-514.
13. Mitani H, Katayama N, Araki H, et al. Activity of interleukin 6 in the differentiation of monocytes to macrophages and dendritic cells. Br J Haematol. 2000;109:288-295.
14. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2:1096-1103.
15. Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: a feasibility study. Blood. 1999;93:2411-2419.
16. Hsu F, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996;2:52-58.
17. + monocytes in multiple myeloma patients. Exp Hematol. 2000;28:931-940.
18. + cells. Br J Haematol. 1998;101:756-765.
19. - dendritic cell precursors. J Immunol. 2001;166:848-854.
20. + precursors. J Immunol. 1997;158:2134-2142.
21. Takamizawa M, Fagnoni F, Mehta-Damani A, Rivas A, Engleman EG. Cellular and molecular basis of human gamma delta T cell activation: role of accessory molecules in alloactivation. J Clin Invest. 1995;95:296-303.
22. + T-cell immune responses induced by dendritic cells. Immunology. 1995;85:467-474.
23. + subset. Cytometry. 2001;45:124-132.
24. Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res. 1997;3:483-490.
25. Gabrilovich DI, Ciernik F, Carbone DP. Dendritic cells in anti-tumor immune responses. I: defective antigen presentation in tumor-bearing hosts. Cell. Immunol. 1996;170:101-110.
26. Pfeiffer S, Gooding RP, Apperley JF, Goldshmidt H, Samson D. Dendritic cells generated from the blood of patients with multiple myeloma are phenotypically and functionally identical to those similarly produced from healthy donors. Br J Haematol. 1997;98:973-982.
27. Raje N, Gong J, Chauhan D, et al. Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences. Blood. 1999;93:1487-1495.
28. Emile C, Fermand JP, Danon F. Interleukin-6 levels in patients with multiple myeloma. Br J Haematol. 1994;86:439-440.
29. Kyrstsonis MC, Dedoussis G, Baxevanis C, Stamatelou M, Maniaris A. Serum interleukin-6 (IL-6) and interleukin-4 (IL-4) in patients with multiple myeloma (MM). Br J Haematol. 1996;92:420-422.
30. Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 1999;59:728-733.
31. Otsuki T, Yamada O, Yata K, et al. Expression and production of interleukin 10 in human myeloma cell lines. Br J Haematol. 2000;111:835-842.
32. 1 and interleukin-10. Blood. 2001;98:2992-2998.
33. + T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur J Immunol. 1996;26:2671-2679.
34. Bocchia M, Bronte V, Colombo MP, et al. Antitumor vaccination: where we stand. Haematologica. 2000;85;1172-1206.